BioStock: Hopeful stock surge in Follicum after suspected analysis error in hair loss project

Many people’s hopes for Follicum’s hair loss project were dashed in May when the company presented top-line results demonstrating that the drug candidate FOL-005 did not show any significant effect compared to placebo. Hopes for the project were rekindled on Wednesday when the company announced possible inaccuracies in the analysis of the results, news that caused the stock to soar. An external review of the study results is now underway and the company’s CEO Kim Arvid Nielsen does not want to make any assumptions until it is completed.

Read the full article at biostock.se:

https://www.biostock.se/en/hopeful-stock-surge-in-follicum-after-suspected-analysis-error-in-hair-loss-project/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se